SoundHealth lands $12.25M Series A for drug-free sinus and sleep wearables
What's the deal? Medical technology firm SoundHealthDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed Series A round led by Shangbay CapitalDealroom has a profile for this one. Try Dealroom →, bringing its total venture funding to $12.25M. The company builds FDA-cleared wearables that treat congestion and sleep disorders without pharmaceuticals.
How it works: SoundHealth uses smartphone facial scanning to build a 3D model of a user's sinus and facial bone structure, then calculates the vibrational frequencies needed for acoustic resonance. Its Sonu band delivers those waves to stimulate nerve pathways and reduce tissue swelling.
The traction: Sonu has delivered more than 500,000 treatment sessions for patients aged 12 and up, positioning it as a non-drug alternative to corticosteroid nasal sprays for allergic and non-allergic rhinitis. Over 1,000 medical and dental professionals nationwide recommend the device.
What's the endgame? SoundHealth is extending its craniofacial dataset into sleep technology with Spatial Sleep, a device that uses personalized acoustic signals to speed sleep onset and deepen continuity. The move applies the same resonance algorithms to a broader consumer market.
Why now? Patients relying on long-term steroid sprays, decongestants, and sedatives face rebound congestion, systemic side effects, and habituation. Drug-free alternatives have historically lacked the clinical rigor and personalized data needed for physician adoption — a gap SoundHealth aims to fill.
"Shangbay's deep expertise in scaling medtech companies will benefit our growth trajectory," said chief executive officer Dr. Paramesh Gopi. Co-founder Dr. Bryant Lin added: "We are thrilled to have them as our Series A lead investor."
The signal: At $12.25M, the round sits in roughly the 21st percentile for size — modest capital for a company already showing regulatory clearance and clinical adoption. It reflects steady investor appetite for non-invasive medtech that targets chronic conditions without the side effects of long-term drug use.
Image credit: Sound Health
